Navigation Links
Insmed Announces First Quarter 2009 Financial Results
Date:5/13/2009

ng diluted net profit (loss) per share 122,698 121,904 INSMED INCORPORATED Consolidated Statements of Cash Flows (in thousands - unaudited) Three Months Ended March 31, 2009 2008 Operating activities Net income (loss) $117,795 $(4,873) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization 205 292 Stock based compensation expense 1,439 133 Gain on sale of asset, net (127,755) - Realized loss on investments - 392 Changes in operating assets and liabilities: Accounts receivable 8 (77) Other assets 44 134 Accounts payable 1,390 (100) Accrued project costs & other (141) 12 Payroll liabilities 4,595 168 Income tax liability 2,794 - Deferred rent (65) - Deferred income (70) 26 Restricted stock unit liability (113) - Asset retirement obligation (2,217) - Interest payable (3) (3) Net cash used in operating activities (2,094) (3,896) Investing activities Cash received
'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 2Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3
Breaking Biology News(10 mins):Vermicompost from pig manure grows healthy hibiscus 2'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Study reveals H1N1 unexpected weakness 2Advanced targeted therapies effective as first line treatment for lung cancer 53419 1Advanced targeted therapies effective as first line treatment for lung cancer 53419 2Advanced targeted therapies effective as first line treatment for lung cancer 53419 3Advanced targeted therapies effective as first line treatment for lung cancer 53419 4Advanced targeted therapies effective as first line treatment for lung cancer 53419 5Advanced targeted therapies effective as first line treatment for lung cancer 53419 6Advanced targeted therapies effective as first line treatment for lung cancer 53419 7Advanced targeted therapies effective as first line treatment for lung cancer 53419 8Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 1Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS SaaS Clinical Trials Collaboration Software 13315 3Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 1Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 2Webinar Offers Tips for Meeting Compliance Communications and Provides HRCI Credit for Human Resource Professionals 53413 3